Welcome to our dedicated page for Olema Pharmaceuticals news (Ticker: OLMA), a resource for investors and traders seeking the latest updates and insights on Olema Pharmaceuticals stock.
Olema Pharmaceuticals, Inc. reports clinical, corporate, and financing developments as a clinical-stage biopharmaceutical company focused on targeted therapies for breast cancer and other cancers. Olema Oncology updates commonly center on palazestrant (OP-1250), an orally available complete estrogen receptor antagonist and selective estrogen receptor degrader, and OP-3136, an orally available KAT6 inhibitor.
Recurring company news covers clinical and preclinical presentations at oncology meetings, endocrine-driven cancer biology, ER+/HER2- breast cancer studies, combination approaches with endocrine therapy and CDK inhibitors, operating results, public offerings, inducement equity grants, and board or management changes.
Olema Oncology (Nasdaq: OLMA) granted stock options to six new employees to purchase an aggregate 176,150 shares of common stock, effective June 1, 2026, under its 2022 Inducement Plan.
Options have a 10-year term, a $12.71 exercise price, and four-year vesting, in line with Nasdaq Listing Rule 5635(c)(4).
Olema Oncology (Nasdaq: OLMA) announced a clinical trial collaboration and supply agreement with Bayer to evaluate KAT6 inhibitor OP-3136 plus NUBEQA (darolutamide) in metastatic castration-resistant prostate cancer.
The Phase 1b/2 trial will enroll about 36 patients, start in H2 2026, and assess safety, tolerability, and preliminary anti-tumor activity. Bayer supplies darolutamide; Olema leads the study, with combined-use data and inventions jointly owned. Olema retains full global commercial and marketing rights to OP-3136 and is also running ongoing OP-3136 studies in solid tumors and ER+/HER2- metastatic breast cancer.
Olema Oncology (Nasdaq: OLMA) reported initial Phase 1 data for OP-3136, an oral KAT6 inhibitor, in advanced solid tumors. OP-3136 monotherapy showed no dose-limiting toxicities up to 45 mg daily, manageable side effects, and evidence of anti-tumor activity with partial responses and target engagement.
Olema Oncology (Nasdaq: OLMA) will participate in three upcoming investor healthcare conferences, each in a fireside chat format.
Events include the TD Cowen Oncology Innovation Summit on May 26, 2026 (virtual), Jefferies Global Healthcare Conference on June 3, 2026 in New York, and Goldman Sachs Global Healthcare Conference on June 9, 2026 in Miami. Webcasts will be accessible via Olema’s investor relations website, subject to host permissions.
Olema Oncology (Nasdaq: OLMA) reported first quarter 2026 financial and operating results and highlighted upcoming clinical milestones in metastatic breast cancer.
The company ended the quarter with $505.3 million in cash and securities, while net loss increased to $53.1 million on higher R&D and G&A expenses supporting late-stage trials.
Top-line data from the pivotal Phase 3 OPERA-01 trial of palazestrant monotherapy are expected in fall 2026. Enrollment continues in the pivotal Phase 3 OPERA-02 trial of palazestrant plus ribociclib, and first clinical data from OP-3136 Phase 1 will be presented at ASCO 2026.
Olema Oncology (Nasdaq: OLMA) granted inducement stock options to five new employees to purchase an aggregate of 154,700 shares, effective May 1, 2026. The options vest over four years (25% after one year, then monthly over three years), have a 10-year term and an exercise price of $14.32 per share, equal to the last reported sale price on May 1, 2026. Awards were approved by the Compensation Committee and granted under the company’s 2022 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Olema Oncology (Nasdaq: OLMA) appointed Prakash Raman, Ph.D., to its Board of Directors on April 29, 2026. Dr. Raman brings over two decades of biopharmaceutical leadership and business development experience, including roles at InduPro Therapeutics, Ribon Therapeutics, Flagship Pioneering, and Novartis.
Olema said the appointment comes as the company advances palazestrant through two Phase 3 trials and prepares for pivotal OPERA-01 data this fall, while also progressing OP-3136, a potential KAT6 inhibitor.
Olema Oncology (NASDAQ: OLMA) will present initial clinical data for OP-3136 from a Phase 1 first-in-human study and a trial-in-progress poster for the Phase 3 OPERA-02 trial at the ASCO Annual Meeting, May 29–June 2, 2026 in Chicago.
The OP-3136 poster (Abstract 3088, Poster 225) is scheduled for May 30, 2026, 1:30pm–4:30pm CT; the OPERA-02 poster (Abstract TPS1152, Poster 261b) is scheduled for June 1, 2026, 1:30pm–4:30pm CT.
Olema Oncology (Nasdaq: OLMA) announced preclinical AACR posters showing palazestrant fully recruits corepressor NCoR1 to achieve complete estrogen receptor antagonism and robust in vitro anti-tumor activity.
Data also show OP-3136, a KAT6 inhibitor, synergizes with palazestrant in ER+/HER2- models; palazestrant is in two Phase 3 trials and OP-3136 is enrolling in Phase 1. Posters presented April 20, 2026 at AACR.
Olema Oncology (Nasdaq: OLMA) granted inducement stock options to four new employees to purchase an aggregate of 188,500 shares, effective April 1, 2026, under the company's 2022 Inducement Plan in compliance with Nasdaq Listing Rule 5635(c)(4).
The options vest over four years (25% after one year, then monthly over three years), have a 10-year term, and an exercise price of $15.12, equal to the last reported Nasdaq sale price on April 1, 2026.